1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

Search for publications

Only original articles, editorials, guidelines.

  • Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M, Perez-Simon JA.

    Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC.

    BONE MARROW TRANSPLANTATION . : . Number of citations: 8

    [doi:10.1038/s41409-024-02483-0]

  • Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV.

    Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.

    BLOOD . 144(23): 2432-2438. Number of citations: 22

    [doi:10.1182/blood.2024024995]

  • Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.

    Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.

    HAEMATOLOGICA . 109(12): 4056-4066. Number of citations: 9

    [doi:10.3324/haematol.2024.285742]

  • Santaliestra M, Garrote M, Noya MS, Pérez-Encinas M, Senín A, Pérez-López R, Ferrer-Marín F, Carreño-Tarragona G, Caballero G, Magro E, Vélez P, Cortés Vázquez MÁ, Moretó A, Angona A, Pastor-Galán I, Guerra JM, García Hernández C, Mata MI, Stuckey R, Gómez-Casares MT, Fox L, Cuevas B, García-Gutiérrez V, Triguero A, Arellano-Rodrigo E, Hernández-Boluda JC, Alvarez-Larrán A.

    Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

    LEUKEMIA . 38(12): 2636-2643.

    [doi:10.1038/s41375-024-02416-2]

  • Quinonero, Isabel Rodenas, Marco-Ayala, Javier, Chen-Liang, Tzu-Hua, de la Cruz-vicente, Fatima, Baumann, Tycho, Navarro, Jose-Tomas, Garcia-Sancho, Alejandro Martin, Martin-Santos, Taida, Lopez-Jimenez, Javier, Andreu, Rafael, Parra, Ester, Usas, Andrea, Alonso, David, Fernandez-Gonzalez, Marta, Rumschisky, Pablo Palomo, Frutos, Laura, Navarro, Jose Luis, Alvarez-Perez, Rosa Maria, Sarandeses, Pilar, Cortes, Montserrat, Tamayo, Pilar, Una, Jon, Martinez-Lorca, Alberto, Ruiz, Cristina, Lozano, Maria Luisa, Ortuno, Francisco Jose.

    The Value of Bone Marrow Assessment by FDG PET/CT, Biopsy and Aspirate in the Upfront Evaluation of Mantle Cell Lymphoma: A Nationwide Cohort Study

    Cancers . 16(24): . Number of citations: 3

    [doi:10.3390/cancers16244189]

  • Hammoud, Miloud, Dominguez-Ruiz, Maria, Assiri, Imane, Rodrigues, Daniel, Aboussair, Nisrine, Lanza, Val F., Villarrubia, Jesus, Colon, Cristobal, Fdil, Naima, del Castillo, Francisco J..

    Metachromatic Leukodystrophy in Morocco: Identification of Causative Variants by Next-Generation Sequencing (NGS)

    Genes . 15(12): . Number of citations: 4

    [doi:10.3390/genes15121515]

  • Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P.

    Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

    Cancers . 16(23): . Number of citations: 4

    [doi:10.3390/cancers16234028]

  • Garcia-Gutierrez V, Huang F, Ashaye A, Dalal M, Laliman-Khara V, Breccia M, Rutherford M, Moradian H, Patos P, Jabbour EJ.

    Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

    Frontiers in Oncology . 14: 1455378-1455378. Number of citations: 9

    [doi:10.3389/fonc.2024.1455378]

  • Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, Coll AP, De Las Heras N, Cortes M, Tenza PV, Pacho MS, Magan AS, Angona A, Cervero C, de Paz R, Cuenca AS, Santaliestra M, Marín JL, Casado LF, García-Gutiérrez V.

    Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

    ANNALS OF HEMATOLOGY . 103(11): 4537-4544. Number of citations: 3

    [doi:10.1007/s00277-024-05906-6]

  • Rodríguez-Mora S, Sánchez-Menéndez C, Bautista-Carrascosa G, Mateos E, Moreno-Serna L, Megías D, Cantón J, García-Gutiérrez V, Murciano-Antón MA, Cervero M, Spivak A, Planelles V, Coiras M.

    Dasatinib interferes with HIV-1 proviral integration and the inflammatory potential of monocyte-derived macrophages from people with HIV.

    BIOCHEMICAL PHARMACOLOGY . 229: 116512-116512. Number of citations: 3

    [doi:10.1016/j.bcp.2024.116512]

  • Pastor-Galán I, Pereira A, Arellano-Rodrigo E, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Hernández-Sánchez A, Ferrer-Marín F, Mora E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, González de Villambrosía S, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín MA, Raya JM, González JA, Cuevas B, Xicoy B, Garrote M, Ferrer B, Pérez-Encinas M, Hernández-Rivas JM, Bellosillo B, Álvarez-Larrán A, Hernández-Boluda JC.

    Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

    LEUKEMIA . 38(11): 2483-2486.

    [doi:10.1038/s41375-024-02389-2]

  • Cederquist GY, Schefflein J, Devlin SM, Shah GL, Shouval R, Hubbeling H, Tringale K, Alarcon Tomas A, Fregonese B, Hajj C, Boardman A, Luna De Abia A, Corona M, Cassanello G, Dahi PB, Lin RJ, Ghione P, Salles G, Perales MA, Palomba ML, Falchi L, Scordo M, Grommes C, Yahalom J, Imber BS.

    CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.

    Blood Advances . 8(19): 5192-5199. Number of citations: 27

    [doi:10.1182/bloodadvances.2024013393]

  • Agudo-Quílez P, Martín-Moro F, Antoñana Ugalde S, Blanco-Peláez E, García-Cosío M, Tenelanda A, Lledó Navarro JL, López-Jiménez J, Zamorano Gómez JL.

    Primary Cardiac Aggressive B-Cell Lymphoma Affecting Right Ventricle and Acute Cardiovascular Events: Multidisciplinary Approach.

    Jacc. Case Reports . 29(19): 102562-102562.

    [doi:10.1016/j.jaccas.2024.102562]

  • Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, Kelly KR, Oehler VG, García-Gutiérrez V, Hjorth-Hansen H, Ernst T, Leip E, Purcell S, Luscan G, Viqueira A, Giles FJ, Hochhaus A.

    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.

    LEUKEMIA . 38(10): 2162-2170. Number of citations: 7

    [doi:10.1038/s41375-024-02372-x]

  • Lorenc R, Shouval R, Flynn JR, Devlin SM, Saldia A, De Abia AL, De Lapuerta MC, Tomas AA, Cassanello G, Leslie LA, Rejeski K, Lin RJ, Scordo M, Shah GL, Palomba ML, Salles G, Park J, Giralt SA, Perales MA, Ip A, Dahi PB.

    Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.

    Transplantation and Cellular Therapy . 30(10): 990-1000. Number of citations: 21

    [doi:10.1016/j.jtct.2024.06.027]

  • Manzanares M, Ramos-Martín F, Rodríguez-Mora S, Casado-Fernández G, Sánchez-Menéndez C, Simón-Rueda A, Mateos E, Cervero M, Spivak AM, Planelles V, Torres M, García-Gutiérrez V, Coiras M.

    Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.

    Frontiers in Pharmacology . 15: 1426974-1426974. Number of citations: 2

    [doi:10.3389/fphar.2024.1426974]

  • Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF.

    Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

    JOURNAL OF CLINICAL ONCOLOGY . 42(27): 3247-3256. Number of citations: 35

    [doi:10.1200/JCO.23.02771]

  • Chatzikonstantinou T, Scarfò L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, Iacoboni G, Demosthenous C, Albi E, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Chatzileontiadou S, Collado R, Davis Z, de Deus Santos MD, Dimou M, Dmitrieva E, Donaldson D, Dos Santos G, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Frygier A, Galimberti S, Galitzia A, Gimeno E, Guarente V, Guieze R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Jaksic O, Kalicinska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou ?, Koren-Michowitz M, Kotsianidis I, Kubova Z, Labrador J, Lad D, Laurenti L, Longval T, Lopez-Garcia A, Marquet J, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Nath UK, Navarro-Bailón A, Olivieri J, Panovska-Stavridis I, Papaioannou M, Pierie C, Puiggros A, Reda G, Rigolin GM, Ruchlemer R, Schipani M, Schiwitza A, Shen Y, Shokralla T, Simkovic M, Smirnova S, Soliman DSA, Stilgenbauer S, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, Vrachiolias G, Vukovic V, Walewska R, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Oscier D, Gozzetti A, Panagiotidis P, Bosch F, Sportoletti P, Espinet B, Pangalis GA, Popov VM, Mulligan S, Angelopoulou M, Demirkan F, Papajík T, Biderman B, Murru R, Coscia M, Tam C, Cuneo A, Gaidano G, Claus R, Stavroyianni N, Trentin L, Antic D, Smolej L, Kalashnikova OB, Catherwood M, Spacek M, Pospisilova S, Doubek M, Nikitin E, Chatzidimitriou A, Ghia P, Stamatopoulos K.

    Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.

    HemaSphere . 8(9): . Number of citations: 1

    [doi:10.1002/hem3.70004]